U.S. Food and Drug Administration

Only one permanent dermal filler has ever cleared the U.S. Food and Drug Administration, and it is approved for just two narrow uses: smoothing nasolabial folds and correcting cheek acne scars. Everything else on the approved list is absorbable, designed to fade over months or a couple of years. That single fact, buried in the agency's device pages, reframes a lot of the marketing a person sees in cosmetic clinics, and it is the sort of thing the regulator publishes plainly while the rest of the industry tends to gloss over it.

Classification as a Class III medical device

For anyone trying to understand what is actually sanctioned for lip and facial injection, the U.S. Food and Drug Administration is the primary document of record. Fillers fall under the Center for Devices and Radiological Health, classified as Class III devices, which is the strictest tier the agency uses. Class III is reserved for products that support or sustain life or carry a meaningful risk of injury, and clearing that bar means a manufacturer has to go through Premarket Approval, a more demanding path than the lighter clearance routes used for lower-risk equipment. The site explains this chain in language a non-specialist can follow, and the classification is the reason the approved-product list is short and specific.

Filler materials and their expected duration

The catalogue itself is organized by material, which turns out to be the most useful way to read it. Hyaluronic acid fillers, the most familiar category, are listed with an expected duration of roughly six to twelve months. Calcium hydroxylapatite runs closer to eighteen months. Poly-L-lactic acid can last up to two years, and collagen sits among the older approved options. The U.S. Food and Drug Administration presents the longevity figures next to the material names, which does something a glossy clinic brochure rarely bothers with: it lets a reader weigh how long they are committing to a given material before anything is injected. The duration ranges are stated as approximate windows, not promises, a level of candor that clinic websites rarely match.

Approved uses limited to adults

Approved indications are spelled out with the same precision. The U.S. Food and Drug Administration limits these products to adults aged twenty-two and older, and the sanctioned uses include lip augmentation, cheek and chin augmentation, correction of nasolabial folds and fine lines around the mouth, restoring volume to the back of the hand, and treating facial lipoatrophy in people with HIV. That last one is a reminder that fillers began partly as a medical correction tool, not purely a cosmetic one. The list is finite, and the agency does not pad it.

Unapproved injection sites flagged by the agency

Alongside the approved uses, the U.S. Food and Drug Administration publishes an explicit roster of unapproved ones, and reading it is faintly alarming in a way that is probably the point. Body contouring injections into the breasts, buttocks, and feet are flagged. So are injections into the glabella, the nose, the area around the eyes, the forehead, and the neck. These are not vague cautions; the U.S. Food and Drug Administration names the anatomical sites where it has not approved filler use, which gives a patient something concrete to bring up with a practitioner before agreeing to a procedure. A site advertising treatment in one of those zones is, by the agency's own reckoning, working off-label, and a patient now has the precise language to push back.

The risk documentation goes further than the usual bruising-and-swelling list. The site carries warnings about vascular occlusion, where filler blocks a blood vessel, and about blindness, an outcome that sounds remote until you see a federal health agency consider it worth documenting in plain sight. That candor is the strongest argument for treating the U.S. Food and Drug Administration as a first stop rather than an afterthought. A clinic has a commercial reason to soften these risks. The regulator does not.

Tools for clinicians and manufacturers

Beyond the patient-facing material, there is a parallel layer aimed at clinicians and manufacturers. Guidance documents for healthcare providers, recall and safety-alert databases, a complaint-reporting mechanism, and published warning letters all sit within reach. The warning letters are worth digging into, since they show which companies have run afoul of the rules and why, in the agency's own words. The complaint-reporting tools also flip the relationship a little: a patient who suffers a bad outcome can feed information back to the U.S. Food and Drug Administration, and that data feeds into how recalls eventually happen. It is a slow loop, but a functioning one, and most commercial sites have nothing equivalent.

The breadth of the U.S. Food and Drug Administration is genuinely vast. The agency oversees food, drugs, medical devices, biologics, cosmetics, radiation-emitting products, veterinary medicine, and tobacco, all under the Department of Health and Human Services. A site covering that much ground risks burying a single topic like lip fillers under a mountain of unrelated regulatory material. To its credit, the U.S. Food and Drug Administration groups the filler content coherently under the devices center, so a determined reader can stay on track rather than wandering through pages about food labeling or drug trials.

The cosmetics side has grown more substantial in recent years. Resources tied to the Modernization of Cosmetics Regulation Act of 2022, usually shortened to MoCRA, give manufacturers compliance guidance that did not exist in this form before. For a consumer, that legislation matters less directly, but it points to the cosmetics arm of the U.S. Food and Drug Administration tightening its grip, which over time should mean more of what gets injected into faces is tracked and accountable. It is worth keeping in mind that fillers themselves are regulated as devices, not as cosmetics, so the MoCRA material speaks more to lotions and makeup than to the injectables a lip-filler patient is researching. The U.S. Food and Drug Administration does not always make that boundary obvious, and a reader can end up in the wrong section without realizing it.

Reading the agency's dense language

Where the experience gets harder is in the reading itself. This is government writing, dense and cross-referenced, and a patient who simply wants a yes-or-no answer about a specific product may have to click through several layers to get there. The information is present and reliable, but it is not packaged for someone in a hurry. Anyone used to a clinic's tidy one-page summary will feel the difference, and not everyone has the patience to translate regulatory prose into a personal decision. That is a description of what the resource is, not a criticism of it.

What also bears mentioning is scope of authority. The U.S. Food and Drug Administration approves products and polices manufacturers, but it does not license or supervise the individual injectors who actually perform procedures. A filler can be fully approved and still be administered badly by someone with inadequate training, and the site cannot help a patient vet the person holding the syringe. A reader leaves with a solid grasp of which materials and uses are sanctioned, and almost no way to judge whether the clinic down the road meets any standard at all. That gap is the one the agency cannot close.